Drug Interactions between Imbruvica and levofloxacin
This report displays the potential drug interactions for the following 2 drugs:
- Imbruvica (ibrutinib)
- levofloxacin
Interactions between your drugs
No interactions were found between Imbruvica and levofloxacin. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.
Imbruvica
A total of 502 drugs are known to interact with Imbruvica.
- Imbruvica is in the drug class BTK inhibitors.
- Imbruvica is used to treat the following conditions:
levofloxacin
A total of 525 drugs are known to interact with levofloxacin.
- Levofloxacin is in the drug class quinolones and fluoroquinolones.
-
Levofloxacin is used to treat the following conditions:
- Anthrax
- Anthrax Prophylaxis
- Bacterial Infection
- Bladder Infection
- Bronchitis
- Chlamydia Infection
- Epididymitis, Sexually Transmitted
- Gonococcal Infection, Disseminated
- Gonococcal Infection, Uncomplicated
- Kidney Infections
- Middle Ear Infections (off-label)
- Nongonococcal Urethritis
- Nosocomial Pneumonia
- Pelvic Inflammatory Disease
- Plague
- Plague Prophylaxis
- Pneumonia
- Prostatitis
- Sinusitis
- Skin and Structure Infection
- Skin or Soft Tissue Infection
- Streptococcal Infection
- Tuberculosis, Active
- Urinary Tract Infection
Drug and food interactions
ibrutinib food
Applies to: Imbruvica (ibrutinib)
GENERALLY AVOID: Coadministration with grapefruit, grapefruit juice, or Seville oranges may significantly increase the plasma concentrations of ibrutinib. The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit. Pharmacokinetic modeling suggests that other moderate CYP450 3A4 inhibitors such as diltiazem and erythromycin may increase ibrutinib systemic exposure (AUC) by 6- to 9-fold under fasting condition. The safety and efficacy of these exposures are unknown. The highest ibrutinib dose evaluated in clinical trials was 12.5 mg/kg (actual doses of 840 to 1400 mg) given for 28 days, which yielded single dose AUC values that were approximately 50% greater than steady-state exposures seen at the highest indicated dose of 560 mg.
ADJUST DOSING INTERVAL: Food increases the oral bioavailability of ibrutinib. The mechanism of interaction is unknown. According to the product labeling, administration with food increases ibrutinib exposure approximately 2-fold compared to administration after overnight fasting.
MANAGEMENT: Patients treated with ibrutinib should avoid consumption of Seville oranges, grapefruit, grapefruit juice, and any supplement containing grapefruit extract. Ibrutinib should be taken once daily at approximately the same time each day.
References (2)
- Cerner Multum, Inc. "UK Summary of Product Characteristics."
- (2013) "Product Information. Imbruvica (ibrutinib)." Pharmacyclics Inc
levoFLOXacin food
Applies to: levofloxacin
ADJUST DOSING INTERVAL: Food may reduce the oral absorption and bioavailability of levofloxacin. According to the drug product labeling, administration of levofloxacin 500 mg with food prolonged the time to peak concentration by 1 hour and decreased the Cmax decreased by 25% following administration of the oral solution and by 14% following administration of the oral tablet.
MANAGEMENT: To ensure maximal and consistent oral absorption, levofloxacin oral solution should be taken at least one hour before or two hours after meals. For administration of the oral solution with continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for one hour before and two hours after the dose of levofloxacin. The oral tablets may be taken without regard to food.
References (1)
- Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT (2009) "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm, 66, p. 1438-67
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.